{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T10:05:42Z","timestamp":1793095542419,"version":"4.5.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100019667","name":"Aesculap Akademie","doi-asserted-by":"publisher","award":["AAG-G-H-2023"],"award-info":[{"award-number":["AAG-G-H-2023"]}],"id":[{"id":"10.13039\/100019667","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005296","name":"Universit\u00e4tsklinikum Regensburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005296","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Periprosthetic joint infection (PJI) is one of the most severe complications in hip arthroplasty, and treatment of PJI is associated with high re-infection rates and significant loss of quality of life for patients, as well as socio-economic impact to health systems. Antimicrobial coating of implants with silver is a promising option to improve the outcome of PJI. However, there is no data from randomized control trials on silver-coated versus standard non-silver-coated implants in patients with PJI. Therefore, the aim of the current study is to assess clinical outcome for the use of silver-coated hip implants (further referred to as IP-coated) versus non-IP-coated implants in patients requiring surgical revision for hip PJI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a multicenter confirmatory interventional randomized controlled superiority single-blinded study with two stages: pilot stage (part A) and pivotal stage (part B). Patients indicated for unilateral cementless acetabular and hip stem revision due to chronic periprosthetic infection planned for single-stage or two-stage surgical procedures are included. Patients will randomly be assigned either to the IP-coated or the non-IP-coated implant group. The primary outcome parameter is infection-free survival within 12\u00a0months after hip PJI. The underlying hypothesis is that the IP coating significantly reduces the risk of periprosthetic reinfection compared to the non-IP-coated implants. Secondary outcome parameters include data on the safety and performance of the prostheses through a 2-year clinical follow-up, including patient-related outcome parameters, such as Harris Hip Score, EQ-5D, radiographical assessment, and blood silver concentrations. An adaptive study design is planned with the inclusion of 268 subjects according to initial sample size calculations. Upon follow-up of 134 patients for 12\u00a0months or inclusion of 90% of the study patients, preliminary study results will be used to re-estimate the sample size, which may be extended up to 400 subjects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The current study aims to fill the evidence gap for the idea of IP-coated implants to reduce re-infection rates in the treatment of hip PJI. To the authors\u2019 best knowledge, this is the first randomized controlled superiority trial evaluating the outcome of a silver-coated versus a non-silver-coated prosthesis for the treatment of hip PJI. The adaptive study design allows an adjustment of the initial sample size to reduce the risk of an underpowered superiority.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov NCT06737809\u00a0(date of publication 17.12.2024).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-026-09541-6","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T01:54:00Z","timestamp":1771293240000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["HIPrevision - a multicenter prospective randomized control superiority trial of antimicrobial IP-coated revision hip prostheses versus non-IP-coated comparators for the revision of periprosthetic hip joint infections"],"prefix":"10.1186","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0208-4650","authenticated-orcid":false,"given":"Volker","family":"Alt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nike","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Baixauli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerzy","family":"Bialecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz","family":"Dreyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Goronzy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Hardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Herold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Kendoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Maenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Rak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Rudert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Sionek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maik","family":"Stiehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Meller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"9541_CR1","doi-asserted-by":"publisher","unstructured":"EPRD Jahresbericht 2023. DE: EPRD Endoprothesenregister Deutschland; 2023 [zitiert 29. Januar 2025]. 175 S. Verf\u00fcgbar unter: https:\/\/doi.org\/10.36186\/reporteprd082023","DOI":"10.36186\/reporteprd082023"},{"key":"9541_CR2","doi-asserted-by":"crossref","unstructured":"Reinhard J, Lang S, Walter N, Schindler M, B\u00e4rtl S, Szymski D, u. a. In-hospital mortality of patients with periprosthetic joint infection: demographic, comorbidity, and complication profiles of 52,286 patients. Bone Jt Open. 26. April 2024 [zitiert 29. Januar 2025];5(4):367\u201373. Verf\u00fcgbar unter: https:\/\/boneandjoint.org.uk\/doi\/10.1302\/2633-1462.54.BJO-2023-0162.R1","DOI":"10.1302\/2633-1462.54.BJO-2023-0162.R1"},{"key":"9541_CR3","doi-asserted-by":"crossref","unstructured":"Szymski D, Walter N, Hierl K, Rupp M, Alt V. Direct hospital costs per case of periprosthetic hip and knee joint infections in Europe \u2014 a systematic review. J Arthroplasty. Juli 2024 [zitiert 29. Januar 2025];39(7):1876\u201381. Verf\u00fcgbar unter: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0883540324000329","DOI":"10.1016\/j.arth.2024.01.032"},{"key":"9541_CR4","doi-asserted-by":"crossref","unstructured":"Shichman I, Sobba W, Beaton G, Polisetty T, Nguyen HB, Dipane MV, u.a. The effect of prosthetic joint infection on work status and quality of life: a multicenter, international study. J Arthroplast. Dezember 2023 [zitiert 3. Februar 2025];38(12):2685\u20132690.e1. Verf\u00fcgbar unter: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S088354032300654X","DOI":"10.1016\/j.arth.2023.06.015"},{"key":"9541_CR5","doi-asserted-by":"crossref","unstructured":"Wildeman P, Rolfson O, S\u00f6derquist B, Wretenberg P, Lindgren V. What are the long-term outcomes of mortality, quality of life, and hip function after prosthetic joint infection of the hip? A 10-year follow-up from Sweden. Clin Orthop Relat Res. Oktober 2021 [zitiert 3. Februar 2025];479(10):2203\u201313. Verf\u00fcgbar unter: https:\/\/journals.lww.com\/10.1097\/CORR.0000000000001838","DOI":"10.1097\/CORR.0000000000001838"},{"key":"9541_CR6","doi-asserted-by":"crossref","unstructured":"Fabritius M, Al-Munajjed AA, Freytag C, J\u00fclke H, Zehe M, Lemarchand T, u.a. Antimicrobial silver multilayer coating for prevention of bacterial colonization of orthopedic implants. Materials. 20. M\u00e4rz 2020 [zitiert 28. Januar 2025];13(6):1415. Verf\u00fcgbar unter: https:\/\/www.mdpi.com\/1996-1944\/13\/6\/1415","DOI":"10.3390\/ma13061415"},{"key":"9541_CR7","doi-asserted-by":"crossref","unstructured":"Khalilpour P, Lampe K, Wagener M, Stigler B, Heiss C, Ullrich MS, u.a. Ag\/SiOx Cy plasma polymer coating for antimicrobial protection of fracture fixation devices. J Biomed Mater Res. Juli 2010 [zitiert 28. Januar 2025];94B(1):196\u2013202. Verf\u00fcgbar unter: https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jbm.b.31641","DOI":"10.1002\/jbm.b.31641"},{"key":"9541_CR8","doi-asserted-by":"crossref","unstructured":"Alt V. Antimicrobial coated implants in trauma and orthopaedics\u2013a clinical review and risk-benefit analysis. Injury. M\u00e4rz 2017 [zitiert 28. Januar 2025];48(3):599\u2013607. Verf\u00fcgbar unter: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0020138316308178","DOI":"10.1016\/j.injury.2016.12.011"},{"key":"9541_CR9","doi-asserted-by":"crossref","unstructured":"Alt V, Heiss C, Rupp M. Treatment of a recurrent periprosthetic joint infection with an intramedullary knee arthrodesis system with low-amount metallic silver coating. J Bone Joint Infect. 20. April 2019 [zitiert 28. Januar 2025];4(3):111\u20134. Verf\u00fcgbar unter: https:\/\/jbji.copernicus.org\/articles\/4\/111\/2019\/","DOI":"10.7150\/jbji.34484"},{"key":"9541_CR10","doi-asserted-by":"crossref","unstructured":"Alt V, Rupp M, Lemberger K, Bechert T, Konradt T, Steinr\u00fccke P, u.a. Safety assessment of microsilver-loaded poly(methyl methacrylate) (PMMA) cement spacers in patients with prosthetic hip infections: results of a prospective cohort study. Bone & Joint Research. August 2019 [zitiert 28. Januar 2025];8(8):387\u201396. Verf\u00fcgbar unter: https:\/\/online.boneandjoint.org.uk\/doi\/10.1302\/2046-3758.88.BJR-2018-0270.R1","DOI":"10.1302\/2046-3758.88.BJR-2018-0270.R1"},{"key":"9541_CR11","doi-asserted-by":"crossref","unstructured":"McNally M, Sousa R, Wouthuyzen-Bakker M, Chen AF, Soriano A, Vogely HC, u.a. The EBJIS definition of periprosthetic joint infection: a practical guide for clinicians. The Bone & Joint J. 1. Januar 2021 [zitiert 28. Januar 2025];103-B(1):18\u201325. Verf\u00fcgbar unter: https:\/\/online.boneandjoint.org.uk\/doi\/10.1302\/0301-620X.103B1.BJJ-2020-1381.R1","DOI":"10.1302\/0301-620X.103B1.BJJ-2020-1381.R1"},{"key":"9541_CR12","unstructured":"Pocket Guide to Diagnosis & Treatment of Periprosthetic Joint Infection (PJI). Pro Implant. [zitiert 28. Januar 2025]. Verf\u00fcgbar unter: https:\/\/pro-implant.org\/product\/pocket-guide-to-diagnosis-treatment-of-periprosthetic-joint-infection-pji\/"},{"key":"9541_CR13","unstructured":"Doyle DJ, Hendrix JM, Garmon EH. American Society of Anesthesiologists Classification. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025 [zitiert 3. Februar 2025]. Verf\u00fcgbar unter: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK441940\/"},{"key":"9541_CR14","doi-asserted-by":"crossref","unstructured":"Ramadanov N, Voss M, Hable R, Hakam HT, Prill R, Salzmann M, u.a. Postoperative Harris Hip Score versus Harris Hip Score difference in hip replacement: what to report? Orthopaedic Surg. Januar 2025 [zitiert 28. Januar 2025];17(1):3\u201321. Verf\u00fcgbar unter: https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/os.14272","DOI":"10.1111\/os.14272"},{"key":"9541_CR15","doi-asserted-by":"crossref","unstructured":"Devlin N, Pickard S, Busschbach J. The development of the EQ-5D-5L and its value sets. In: Devlin N, Roudijk B, Ludwig K, Herausgeber. Value Sets for EQ-5D-5L. Cham: Springer International Publishing; 2022 [zitiert 28. Januar 2025]. S. 1\u201312. Verf\u00fcgbar unter: https:\/\/link.springer.com\/10.1007\/978-3-030-89289-0_1","DOI":"10.1007\/978-3-030-89289-0_1"},{"key":"9541_CR16","doi-asserted-by":"crossref","unstructured":"Fabritius M, Al-Munajjed AA, Freytag C, J\u00fclke H, Zehe M, Lemarchand T, u.a. Antimicrobial silver multilayer coating for prevention of bacterial colonization of orthopedic implants. Materials. 20. M\u00e4rz 2020 [zitiert 27. Januar 2026];13(6):1415. Verf\u00fcgbar unter: https:\/\/www.mdpi.com\/1996-1944\/13\/6\/1415","DOI":"10.3390\/ma13061415"},{"key":"9541_CR17","doi-asserted-by":"crossref","unstructured":"Pag\u00e8s G, Hammer M, Grand JG, Irubetagoyena I. Long-term outcome of tibial plateau leveling osteotomy using an antimicrobial silver-based coated plate in dogs. Abu-Seida AM, Herausgeber. PLoS ONE. 12. August 2022 [zitiert 27. Januar 2026];17(8):e0272555. Verf\u00fcgbar unter: https:\/\/dx.plos.org\/10.1371\/journal.pone.0272555","DOI":"10.1371\/journal.pone.0272555"},{"key":"9541_CR18","doi-asserted-by":"crossref","unstructured":"Wassmer G, Brannath W. Group Sequential and Confirmatory Adaptive Designs in Clinical Trials. Cham: Springer Nature Switzerland; 2025 [zitiert 27. Januar 2026]. (Springer Series in Pharmaceutical Statistics). Verf\u00fcgbar unter: https:\/\/link.springer.com\/10.1007\/978-3-031-89669-9","DOI":"10.1007\/978-3-031-89669-9"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-026-09541-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09541-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09541-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T13:07:57Z","timestamp":1771852077000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13063-026-09541-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9541"],"URL":"https:\/\/doi.org\/10.1186\/s13063-026-09541-6","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"assertion":[{"value":"2 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"\u2022\u00a0Poland: Bioethics Committee Dom Nauki CMKP, Number 67\/2024\u2022\u00a0Germany: Ethik-Kommission des Landes Berlin, 24-665-MP Haupt\u2013IV E 17\u2022\u00a0Spain: CEIm del Hospital Universitario y Polit\u00e9cnico la Fe de Valencia Research Ethics Committee, Acta no 574","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"174"}}